^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FT522

    i
    Other names: FT522, ADR-armed iPSC-derived CAR NK cells, ADR+ CAR19 iNK cells
    Associations

    News

    Trials
    Company:
    Fate Therap
    Drug class:
    CD19 inhibitor, NK cell stimulant, CD137 modulator
    Related drugs:
    Associations

    News

    Trials
    3ms
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=20, Completed, Fate Therapeutics | Recruiting --> Completed | N=166 --> 20 | Trial completion date: Jun 2044 --> Jun 2025 | Trial primary completion date: Jun 2029 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • FT522
    over1year
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=166, Recruiting, Fate Therapeutics | N=322 --> 166
    Enrollment change • Combination therapy
    |
    cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • FT522
    over1year
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=322, Recruiting, Fate Therapeutics | Trial completion date: Dec 2039 --> Jun 2044 | Trial primary completion date: Dec 2024 --> Jun 2029
    Trial completion date • Trial primary completion date • Combination therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV • FT522
    2years
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=322, Recruiting, Fate Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV • FT522
    over2years
    FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) (clinicaltrials.gov)
    P1, N=322, Not yet recruiting, Fate Therapeutics
    New P1 trial • Combination therapy
    |
    cyclophosphamide • bendamustine • fludarabine IV • FT522